Who founded Gilgamesh Pharmaceuticals?

Gilgamesh Pharmaceuticals was founded by Jonathan Sporn, Andrew Kruegel, Dalibor Sames, JONATHAN SPORN, Andrew Kruegel, Ph.D., Jonathan Sporn, M.D. in 2019.

Who are Gilgamesh Pharmaceuticals's investors?

Gilgamesh Pharmaceuticals's investors include Aera VC, Frontera Technology Ventures, Frontier Path VC, James Beshara Fund, JLS, Magnetic Ventures, Noetic, Prime Movers Lab and 8 more.

How much funding has Gilgamesh Pharmaceuticals raised?

Gilgamesh Pharmaceuticals has disclosed $111.8M raised across 6 of its 7 known rounds.

Where is Gilgamesh Pharmaceuticals headquartered?

Gilgamesh Pharmaceuticals is headquartered in New York City, US.

Gilgamesh Pharmaceuticals

YC S20

New York City, US · Founded 2019 · Delaware corporation · 15 employees · 16 known investors

Find your way into Gilgamesh Pharmaceuticals

680 people in our graph share verified history with the Gilgamesh Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Teresa Chanunlockedknows Jonathan Sporn · together at JNJ (overlapped)

×6knows the team · via Columbia University

knows the team · via JNJ

×3knows the team · via NIH

knows the team · via Columbia University in the City of New York

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.

AI & Machine Learning Biotech Digital Health Healthtech Therapeutics Psychedelics Mental HealthUnited States of AmericaAmerica / CanadaFully Remote

Founders & leadership· Y Combinator alumni (S20)

Jonathan Sporn inCo-founder · Chief Executive Officer and Chairman of the BoardJonathan Sporn holds a BS from Duke University and an MD from the University of Miami. He has held leadership roles including Chief of Psychiatry in the Boston area, researcher at Mass General Hospital and the NIH, and clinical positions at Johnson & Johnson and Pfizer in neuroscience and psychiatry. He previously founded Perception Neuroscience, which exited, and is currently an Assistant Professor of Psychiatry and Experimental Therapeutics at Columbia University while founding Gilgamesh Pharmaceuticals.

Andrew Kruegel inFounderAndrew Kruegel is a medicinal chemist and pharmacologist who has focused on drug design and preclinical development for psychiatric treatment. He has also developed expertise in business operations, fundraising, and intellectual property strategy.

Dalibor Sames inCo-FounderChemistry professor at Columbia University with research background in synthetic and medicinal chemistry, molecular imaging, and neuropharmacology. His work has included research on C-H bond functionalization methods, fluorescent probes for synaptic imaging, and the pharmacology of various natural alkaloids.

JONATHAN SPORN inCo-founder · Chief Executive Officer and Chairman of the BoardJonathan Sporn holds a BS from Duke University and an MD from the University of Miami. He has held leadership roles including Chief of Psychiatry in the Boston area, researcher at the NIH and Mass General Hospital, psychiatry and neurology researcher at Johnson & Johnson, and Clinical Disease Area Expert in Neuroscience at Pfizer. He previously founded Perception Neuroscience, which exited, and is now Founder of Gilgamesh Pharmaceuticals; he also serves as Assistant Professor of Psychiatry and Experimental Therapeutics at Columbia University.

Andrew Kruegel, Ph.D.Co-founder

Jonathan Sporn, M.D.inCo-founder · Chief Executive Officer and Chairman of the BoardBoard-certified psychiatrist with training in psychiatry at Tufts and Harvard, who served as chief of psychiatry in the Boston area and conducted research on glutamate in mood disorders at Massachusetts General Hospital and the NIH intramural program. He held internal drug portfolio roles at Johnson & Johnson and Pfizer before founding Perception Neuroscience (acquired by ATAI Life Sciences) and now serves as President and CEO of Gilgamesh Pharmaceuticals.

Thomas Kevin Murphy, Ph.D.Executive

Investors · 16

Aera VCSingapore · $25K – $5M

Frontera Technology VenturesTexas

Frontier Path VCLondon

James Beshara FundLos Angelesvia James J Beshara · inferred

JLSNew York

Magnetic VenturesBoston · $1M – $6M

NoeticToronto

Prime Movers LabJackson · $2M – $30Mvia Gaetano Crupi · board

PsyMed VenturesBerkeley

Strawberry Creek VenturesManchester

Y CombinatorSan Francisco · $500K

Alumni VenturesreportedManchester · $100K – $10M

Gron Ventures, LlcreportedNewport Beach

Negev CapitalreportedTel Aviv

Palo SantoreportedHighland Park

Satori CapitalreportedDallas

Funding

SEC filings, press & company announcements

$111.8M disclosed across 6 of 7 rounds · 2020–2026

$60MSeries AMar 2026
Source ↗

▶$13.8MraisedMay 2022 · 14 investors · Pharmaceuticals

Rule 506(c)